Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer

PURPOSE: ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC). ARN-509 inhibits AR nuclear translocation and AR binding to androgen response elements and, unlike bicalutamide, does not exhibit agonist properties in the context of AR ov...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Rathkopf, Dana E., Morris, Michael J., Fox, Josef J., Danila, Daniel C., Slovin, Susan F., Hager, Jeffrey H., Rix, Peter J., Chow Maneval, Edna, Chen, Isan, Gönen, Mithat, Fleisher, Martin, Larson, Steven M., Sawyers, Charles L., Scher, Howard I.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2013
Soggetti:
Original Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3782148/
https://ncbi.nlm.nih.gov/pubmed/24002508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.50.1684
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi